Prostate cancer prevention: review of target populations, pathological biomarkers, and chemopreventive agents.
Montironi
R
R
Institute of Pathological Anatomy and Histopathology, University of Ancona, Ospedale Regionale, Italy. r.montironi@popcsi.unian.it
Mazzucchelli
R
R
Marshall
J R
JR
Bartels
P H
PH
D000230:Adenocarcinoma / Q000175:diagnosis / Q000235:genetics / Q000517:prevention & control*; D000726:Androgen Antagonists / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004032:Diet; D004195:Disease Models, Animal; D000518:Eflornithine / Q000627:therapeutic use; D020022:Genetic Predisposition to Disease; D006801:Humans; D008297:Male; D019048:Prostatic Intraepithelial Neoplasia / Q000175:diagnosis; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000517:prevention & control*; D012176:Retinoids / Q000627:therapeutic use
D000726:Androgen Antagonists; D000970:Antineoplastic Agents; D012176:Retinoids; D000518:Eflornithine